TABLE 1.
Baseline characteristics
| Factor | Group | Sorafenib (n = 65) | Lenvatinib (n = 36) | p‐Value |
| BCLC stage, n (%) | A | 1 (1.5) | 0 (0.0) | 0.165 |
| B | 32 (49.2) | 24 (66.7) | ||
| C | 32 (49.2) | 12 (33.3) | ||
| 0 | 44 (67.7) | 21 (58.3) | 0.21 | |
| ECOG‐PS, n (%) | 1 | 18 (27.7) | 15 (41.7) | |
| 2 | 3 (4.6) | 0 (0.0) | ||
| Gender, n (%) | F | 20 (30.8) | 9 (25.0) | 0.648 |
| M | 45 (69.2) | 27 (75.0) | ||
| Age, years median (range) | 80 (75, 98) | 81 (75, 93) | 0.217 | |
| Etiology, n (%) | ALD | 8 (12.3) | 8 (22.2) | 0.487 |
| HBV | 3 (4.6) | 1 (2.8) | ||
| HBV + HCV | 1 (1.5) | 0 (0.0) | ||
| HCV | 38 (58.5) | 16 (44.4) | ||
| Others | 15 (23.1) | 11 (30.6) | ||
| Major vascular invasion (%) | No | 56 (86.2) | 32 (88.9) | 0.767 |
| Yes | 9 (13.8) | 4 (11.1) | ||
| Extrahepatic spread (%) | Yes | 27 (41.5) | 7 (19.4) | 0.029 |
| No | 38 (58.5) | 29 (80.6) | ||
| Tumor volume ≥ 50% (%) | No | 57 (89.1) | 33 (91.7) | 1 |
| Yes | 7 (10.9) | 3 (8.3) | ||
| Child‐Pugh score (%) | 5 | 30 (46.2) | 21 (60.0) | 0.464 |
| 6 | 27 (41.5) | 10 (28.6) | ||
| 7 | 7 (10.8) | 3 (8.6) | ||
| 8 | 1 (1.5) | 1 (2.9) | ||
| ALBI score, median (range) | −2.14 (−2.93, −1.33) | −2.36 (−3.21, −1.35) | 0.105 | |
| Baseline DCP, median (range) | 267 (8.90, 54 104) | 606 (10.2, 427 125) | 0.442 | |
| Baseline AFP median (range) | 36.6 (1.80, 69 100) | 30.4 (1.6, 97 455) | 0.633 | |
| mG8 score | 11 (8, 15) | 12 (8, 14) | 0.09 |
Abbreviations: BCLS stage: Barcelona Clinic Liver Cancer stage; ECOG‐PS: the Eastern Cooperative Oncology Group Scale of Performance Status; ALBI score: albumin–bilirubin score; DCP: des‐gamma‐carboxy prothrombin; AFP: α‐fetoprotein;mG8 score: modified Geriatric 8 score.